Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carotuximab + sorafenib
- Development stage
- Unknown
- Lead developer
- TRACON Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**carotuximab + sorafenib** is an investigational combination therapy for cancer, notably hepatocellular carcinoma (HCC). Carotuximab (TRC105) is a monoclonal antibody targeting endoglin (CD105), a protein involved in angiogenesis, while sorafenib is a small molecule multikinase inhibitor that targets Raf kinases, vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and others, suppressing tumor cell proliferation and angiogenesis. The combination aims to provide additive or synergistic anti-tumor effects through dual inhibition of angiogenic pathways. This regimen has shown tolerability and promising partial response rates in early-phase clinical trials[4].
- Brand names
- Nexavar
- Other names
- carotuximabTRC105TRC-105TRC 105sorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)ENG (Integrin Beta 6)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on carotuximab + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carotuximab + sorafenib.